ArticleBMC veterinary research2025
Serovars and antimicrobial resistance profiles of Actinobacillus pleuropneumoniae isolates from clinical-case pigs in Taiwan.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Actinobacillus pleuropneumoniae - today's perspective on advances and challenges (2017- 2026).BMC veterinary research · 2026Review
- Atypical multidrug-resistant serotype 1Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPleuropneumonia remains an important challenge to swine production worldwide. The causative agent, Actinobacillus pleuropneumoniae serovar prevalence in countries can change over time. Few Taiwanese A. pleuropneumoniae prevalence studies have been published, and recent large-scale investigations remain notably scarce. This study aimed to identify the serovars and antimicrobial sensitivity of 96 current Taiwanese A. pleuropneumoniae clinical isolates.
resultsAmong the 99 A. pleuropneumoniae determinations, 40 (40.4%) were serovar 15, 29 (29.3%) were serovar 5, 15 (15.2%) were serovar 1, 11 (11.1%) were serovar 7, and 4 (4.0%) were serovar 2. Therefore serovar 15 was the most predominant between 2015 and 2022. Resistance of the isolates was minimal to ceftiofur (3.2%), cephalexin (5.2%), cephalothin (6.3%) and enrofloxacin (9.3%), moderate to gentamicin (28.4%), and high for florfenicol, amoxicillin and ampicillin (45.1-68.4%).
conclusionsThis study updates the serovar and antimicrobial sensitivity patterns of Taiwanese clinical A. pleuropneumoniae isolates, showing that serovars 15, 5, 1, 7, and 2 collectively predominate in clinical outbreaks. Local A. pleuropneumoniae isolates exhibited high resistance to antimicrobials currently used in the Taiwanese pig production, such as amoxicillin, ampicillin, and florfenicol. However, there was low resistance to cephalexin, cephalothin, tilmicosin and lincospectin (injectable only) which can be recommended for current use in Taiwan, considering both efficacy and public health risks. Notably, isolates of the same serovar collected from the same farm on the same day occasionally displayed distinct resistance patterns, emphasizing the complex dynamics of antimicrobial resistance. Our data will help veterinarians and producers refine vaccination and treatment protocols, highlighting the importance of ongoing surveillance to respond effectively to evolving resistance trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.